TWI476199B - 用於治療疾病之巨環衍生物 - Google Patents

用於治療疾病之巨環衍生物 Download PDF

Info

Publication number: TWI476199B
Authority: TW; Taiwan
Prior art keywords: group; alkyl; cycloalkyl; hydrogen; aryl
Prior art date: 2012-03-06

Application number

TW102107486A

Other languages

English (en)

Chinese (zh)

Other versions

TW201350484A (zh

Inventor

Simon Bailey

Benjamin Joseph Burke

Michael Raymond Collins

Jingrong Jean Cui

Judith Gail Deal

Robert Louis Hoffman

Qinhua Huang

Ted William Johnson

Robert Steven Kania

John Charles Kath

Phuong Thi Quy Le

Michele Ann Mctigue

Cynthia Louise Palmer

Paul Francis Richardson

Neal William Sach

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-06

Filing date

2013-03-04

Publication date

2015-03-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI476199(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-04 Application filed by Pfizer filed Critical Pfizer

2013-12-16 Publication of TW201350484A publication Critical patent/TW201350484A/zh

2015-03-11 Application granted granted Critical

2015-03-11 Publication of TWI476199B publication Critical patent/TWI476199B/zh

Links

238000011282 treatment Methods 0.000 title claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 2
201000010099 disease Diseases 0.000 title 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 1343
229910052739 hydrogen Inorganic materials 0.000 claims description 440
239000001257 hydrogen Substances 0.000 claims description 438
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 401
125000003118 aryl group Chemical group 0.000 claims description 333
GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 333
125000004093 cyano group Chemical group *C#N 0.000 claims description 293
125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 274
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 270
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 265
229910052736 halogen Inorganic materials 0.000 claims description 230
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 226
150000002367 halogens Chemical class 0.000 claims description 225
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 162
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 150
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 128
150000001875 compounds Chemical class 0.000 claims description 124
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 105
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 99
150000003839 salts Chemical class 0.000 claims description 67
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 61
125000001072 heteroaryl group Chemical group 0.000 claims description 60
ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 59
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 55
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 52
229910052799 carbon Inorganic materials 0.000 claims description 42
150000003852 triazoles Chemical class 0.000 claims description 40
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 32
150000003536 tetrazoles Chemical class 0.000 claims description 32
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 31
230000002159 abnormal effect Effects 0.000 claims description 25
230000035772 mutation Effects 0.000 claims description 25
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 23
241000124008 Mammalia Species 0.000 claims description 23
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 20
206010028980 Neoplasm Diseases 0.000 claims description 19
201000011510 cancer Diseases 0.000 claims description 19
108020001507 fusion proteins Proteins 0.000 claims description 17
102000037865 fusion proteins Human genes 0.000 claims description 16
230000001404 mediated effect Effects 0.000 claims description 12
229910052757 nitrogen Inorganic materials 0.000 claims description 12
-1 C 3 -C 6 cycloalkyl Hydrogen Chemical compound 0.000 claims description 11
238000006467 substitution reaction Methods 0.000 claims description 11
108091000080 Phosphotransferase Proteins 0.000 claims description 10
102000020233 phosphotransferase Human genes 0.000 claims description 10
102220197961 rs1057519784 Human genes 0.000 claims description 9
102220198074 rs1057519859 Human genes 0.000 claims description 9
208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 8
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 5
229910052727 yttrium Inorganic materials 0.000 claims description 5
125000000304 alkynyl group Chemical group 0.000 claims description 4
230000004663 cell proliferation Effects 0.000 claims description 4
206010060862 Prostate cancer Diseases 0.000 claims description 3
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
206010017758 gastric cancer Diseases 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
201000006845 reticulosarcoma Diseases 0.000 claims description 3
208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
201000011549 stomach cancer Diseases 0.000 claims description 3
206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
206010029260 Neuroblastoma Diseases 0.000 claims description 2
125000002723 alicyclic group Chemical group 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
201000010279 papillary renal cell carcinoma Diseases 0.000 claims description 2
206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
150000002431 hydrogen Chemical class 0.000 claims 16
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical group C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 claims 2
241000282465 Canis Species 0.000 claims 1
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Chemical group C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 claims 1
IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 claims 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 206
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 55
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 46
125000000217 alkyl group Chemical group 0.000 description 30
RSTKLPZEZYGQPY-UHFFFAOYSA-M 3-(indol-3-yl)pyruvate Chemical group C1=CC=C2C(CC(=O)C(=O)[O-])=CNC2=C1 RSTKLPZEZYGQPY-UHFFFAOYSA-M 0.000 description 26
239000002585 base Substances 0.000 description 24
230000010261 cell growth Effects 0.000 description 21
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 21
101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 20
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 19
125000001424 substituent group Chemical group 0.000 description 16
125000000753 cycloalkyl group Chemical group 0.000 description 11
125000006615 aromatic heterocyclic group Chemical group 0.000 description 10
125000000623 heterocyclic group Chemical group 0.000 description 9
238000000034 method Methods 0.000 description 9
150000003254 radicals Chemical class 0.000 description 9
229940049706 benzodiazepine Drugs 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
239000002246 antineoplastic agent Substances 0.000 description 7
125000004432 carbon atom Chemical group C* 0.000 description 7
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 6
239000002146 L01XE16 - Crizotinib Substances 0.000 description 6
150000001502 aryl halides Chemical class 0.000 description 6
KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 6
229960005061 crizotinib Drugs 0.000 description 6
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical group C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 6
125000005843 halogen group Chemical group 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 5
229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
150000001345 alkine derivatives Chemical class 0.000 description 4
239000011737 fluorine Substances 0.000 description 4
229910052731 fluorine Inorganic materials 0.000 description 4
230000004927 fusion Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
125000001931 aliphatic group Chemical group 0.000 description 3
150000001336 alkenes Chemical class 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000004037 angiogenesis inhibitor Substances 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
229910000063 azene Inorganic materials 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
230000008094 contradictory effect Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
125000003226 pyrazolyl group Chemical group 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 2
101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
125000004649 C2-C8 alkynyl group Chemical group 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical group CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
125000006001 difluoroethyl group Chemical group 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000002678 macrocyclic compounds Chemical class 0.000 description 2
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
125000000547 substituted alkyl group Chemical group 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000005945 translocation Effects 0.000 description 2
229910052720 vanadium Inorganic materials 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
IUDIUFOSOKJWBY-UHFFFAOYSA-N 1H-benzo[i][1,2]benzodiazepine Chemical compound N1N=CC=CC2=CC=C(C=CC=C3)C3=C12 IUDIUFOSOKJWBY-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
206010061424 Anal cancer Diseases 0.000 description 1
206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
208000007860 Anus Neoplasms Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
206010006143 Brain stem glioma Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 description 1
ISEPGJQCJFIDQG-UHFFFAOYSA-N CCCCCCCCCCCCCC.O1N=NC=CC=C1 Chemical compound CCCCCCCCCCCCCC.O1N=NC=CC=C1 ISEPGJQCJFIDQG-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
229940123587 Cell cycle inhibitor Drugs 0.000 description 1
206010007953 Central nervous system lymphoma Diseases 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
201000001342 Fallopian tube cancer Diseases 0.000 description 1
208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 1
101000956807 Homo sapiens Leukocyte tyrosine kinase receptor Proteins 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
229930194542 Keto Natural products 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
102100038420 Leukocyte tyrosine kinase receptor Human genes 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000032271 Malignant tumor of penis Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229940121849 Mitotic inhibitor Drugs 0.000 description 1
101100091501 Mus musculus Ros1 gene Proteins 0.000 description 1
WCCZJIBNVKKGFU-UHFFFAOYSA-N ONNCCCCCCCCCCC Chemical compound ONNCCCCCCCCCCC WCCZJIBNVKKGFU-UHFFFAOYSA-N 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
206010061336 Pelvic neoplasm Diseases 0.000 description 1
208000002471 Penile Neoplasms Diseases 0.000 description 1
206010034299 Penile cancer Diseases 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
102000007982 Phosphoproteins Human genes 0.000 description 1
108010089430 Phosphoproteins Proteins 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
208000023915 Ureteral Neoplasms Diseases 0.000 description 1
206010046392 Ureteric cancer Diseases 0.000 description 1
206010046431 Urethral cancer Diseases 0.000 description 1
206010046458 Urethral neoplasms Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
201000005188 adrenal gland cancer Diseases 0.000 description 1
208000024447 adrenal gland neoplasm Diseases 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
230000003388 anti-hormonal effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
238000011319 anticancer therapy Methods 0.000 description 1
201000011165 anus cancer Diseases 0.000 description 1
125000000732 arylene group Chemical group 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000005605 benzo group Chemical group 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024207 chronic leukemia Diseases 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
208000030381 cutaneous melanoma Diseases 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
201000004101 esophageal cancer Diseases 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
239000003394 isomerase inhibitor Substances 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical group C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
125000000468 ketone group Chemical group 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
201000005249 lung adenocarcinoma Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
108700009251 p80(NPM-ALK) Proteins 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005855 radiation Effects 0.000 description 1
102000027426 receptor tyrosine kinases Human genes 0.000 description 1
108091008598 receptor tyrosine kinases Proteins 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
102000034285 signal transducing proteins Human genes 0.000 description 1
108091006024 signal transducing proteins Proteins 0.000 description 1
230000011664 signaling Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000003708 skin melanoma Diseases 0.000 description 1
201000002314 small intestine cancer Diseases 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
206010062261 spinal cord neoplasm Diseases 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
201000002510 thyroid cancer Diseases 0.000 description 1
125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-L tyrosinate(2-) Chemical compound [O-]C(=O)C(N)CC1=CC=C([O-])C=C1 OUYCCCASQSFEME-UHFFFAOYSA-L 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
206010046885 vaginal cancer Diseases 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)

TW102107486A 2012-03-06 2013-03-04 用於治療疾病之巨環衍生物 TWI476199B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261607485P	2012-03-06	2012-03-06
US201361759307P	2013-01-31	2013-01-31

Publications (2)

Publication Number	Publication Date
TW201350484A TW201350484A (zh)	2013-12-16
TWI476199B true TWI476199B (zh)	2015-03-11

Family

ID=48142828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW102107486A TWI476199B (zh)	2012-03-06	2013-03-04	用於治療疾病之巨環衍生物

Country Status (45)

Country	Link
US (2)	US8680111B2 (mo)
EP (1)	EP2822953B9 (mo)
JP (2)	JP5823066B2 (mo)
KR (1)	KR101692600B1 (mo)
CN (1)	CN104169286B (mo)
AP (1)	AP2014007881A0 (mo)
AR (1)	AR090230A1 (mo)
AU (1)	AU2013229173B2 (mo)
BR (1)	BR112014022106B1 (mo)
CA (1)	CA2863892C (mo)
CL (1)	CL2014002084A1 (mo)
CO (1)	CO7061081A2 (mo)
CR (1)	CR20140370A (mo)
CY (2)	CY1118771T1 (mo)
DK (1)	DK2822953T5 (mo)
DO (1)	DOP2014000188A (mo)
EA (1)	EA026155B9 (mo)
ES (1)	ES2621220T3 (mo)
FR (1)	FR19C1062I2 (mo)
GE (1)	GEP201606560B (mo)
GT (1)	GT201400187A (mo)
HR (1)	HRP20170287T2 (mo)
HU (2)	HUE034118T2 (mo)
IL (1)	IL234062A (mo)
LT (2)	LT2822953T (mo)
LU (1)	LUC00131I2 (mo)
MD (1)	MD4590C1 (mo)
ME (1)	ME02630B (mo)
MX (1)	MX350844B (mo)
MY (1)	MY169142A (mo)
NI (1)	NI201400102A (mo)
NL (1)	NL301006I2 (mo)
NO (1)	NO2019034I1 (mo)
NZ (1)	NZ627900A (mo)
PE (1)	PE20142339A1 (mo)
PH (1)	PH12014501992A1 (mo)
PL (1)	PL2822953T3 (mo)
PT (1)	PT2822953T (mo)
RS (1)	RS55814B1 (mo)
SG (1)	SG11201404451TA (mo)
SI (1)	SI2822953T1 (mo)
TW (1)	TWI476199B (mo)
UY (1)	UY34657A (mo)
WO (1)	WO2013132376A1 (mo)
ZA (1)	ZA201406244B (mo)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS56015B1 (sr)	2013-01-31	2017-09-29	Vertex Pharma	Piridon amidi kao modulatori natrijumovih kanala
CA2916605C (en)	2013-06-28	2018-04-24	Pfizer Inc.	Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh)	2013-10-01	2015-04-15	南京波尔泰药业科技有限公司	用于治疗增殖性疾病的大环化合物
CA2931550C (en)	2013-12-13	2023-09-26	Vertex Pharmaceuticals Incorporated	Prodrugs of pyridone amides useful as modulators of sodium channels
ES2933350T3 (es)	2014-01-24	2023-02-06	Turning Point Therapeutics Inc	Macrociclos de diarilo como moduladores de proteína quinasas
TWI672141B (zh)	2014-02-20	2019-09-21	美商醫科泰生技	投予ｒｏｓ１突變癌細胞之分子
CN103772272A (zh) *	2014-03-04	2014-05-07	定陶县友帮化工有限公司	2-boc-氨基-3-羟基-5-溴吡啶的合成方法
WO2016026423A1 (en) *	2014-08-20	2016-02-25	Teligene Ltd	Substituted macrocycles useful as kinases inhibitors and methods of use thereof
EP3183256A4 (en) *	2014-08-20	2018-05-30	Teligene Ltd.	Substituted macrocycles useful as kinases inhibitors and methods of use thereof
KR102569226B1 (ko) *	2014-10-13	2023-08-22	아트린 파마슈티컬스 엘엘씨	운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제
CN107207471B (zh)	2014-12-02	2020-06-26	伊尼塔公司	用于治疗神经母细胞瘤的组合
KR102584344B1 (ko) *	2015-01-16	2023-09-27	추가이 세이야쿠 가부시키가이샤	병용 의약
AU2016287568B2 (en)	2015-07-02	2020-08-20	Turning Point Therapeutics, Inc.	Chiral diaryl macrocycles as modulators of protein kinases
RU2765181C2 (ru)	2015-07-06	2022-01-26	Тёрнинг Поинт Терапьютикс, Инк.	Полиморфная форма диарильного макроцикла
PT3733187T (pt)	2015-07-21	2024-11-08	Turning Point Therapeutics Inc	Macrociclo de diarilo quiral e utilização do mesmo no tratamento do cancro
PT3798222T (pt)	2015-07-31	2024-01-22	Pfizer	Forma cristalina de base livre de lorlatinib
JP2018529719A (ja)	2015-09-30	2018-10-11	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
AU2016370846B2 (en)	2015-12-18	2022-08-25	Ignyta, Inc.	Combinations for the treatment of cancer
WO2017148325A1 (zh)	2016-03-03	2017-09-08	深圳市塔吉瑞生物医药有限公司	一种大环化合物及包含该化合物的组合物
CN105646355A (zh) *	2016-04-07	2016-06-08	戊言医药科技（上海）有限公司	3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
CN105732355A (zh) *	2016-04-07	2016-07-06	戊言医药科技（上海）有限公司	1-(5-氟-2-碘苯基)乙酮的制备方法
US11078215B2 (en) *	2016-04-08	2021-08-03	Pfizer Inc.	Crystalline forms of lorlatinib maleate
US10301324B2 (en)	2016-04-12	2019-05-28	Atrin Pharmaceuticals LLC	Ataxia telengiectasia and rad3-related (ATR) inhibitors and methods of their use
CN105801603B (zh) *	2016-04-13	2018-10-02	成都倍特药业有限公司	一种具有大环结构的alk抑制剂及其制备方法
US10689400B2 (en)	2016-07-28	2020-06-23	Turning Point Therapeutics, Inc.	Macrocycle kinase inhibitors
US11071721B2 (en) *	2016-12-02	2021-07-27	Genentech, Inc.	Bicyclic amide compounds and methods of use thereof
WO2018137679A1 (en) *	2017-01-25	2018-08-02	Teligene Ltd	Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
EP3625214B1 (en)	2017-05-16	2022-07-06	Vertex Pharmaceuticals Incorporated	Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
US11485733B2 (en)	2017-06-30	2022-11-01	Bayer Animal Health Gmbh	Azaquinoline derivatives
KR102718538B1 (ko)	2017-07-19	2024-10-21	이그니타, 인코포레이티드	엔트렉티닙을 포함하는 약학적 조성물
CN111182903A (zh)	2017-07-28	2020-05-19	特普医药公司	巨环化合物及其用途
HUE062926T2 (hu) *	2017-10-10	2023-12-28	Pfizer	Lorlatinib mint szabad bázis hidrátjának kristályos formája
CN111225662B (zh)	2017-10-17	2022-11-22	伊尼塔公司	药物组合物和剂型
US11179412B2 (en)	2017-12-04	2021-11-23	University of Pittsburgh—of the Commonwealth System of Higher Education	Methods of treating conditions involving elevated inflammatory response
LT3728271T (lt)	2017-12-19	2022-12-12	Turning Point Therapeutics, Inc.	Makrocikliniai junginiai, skirti ligų gydymui
US11529337B2 (en)	2018-02-12	2022-12-20	Vertex Pharmaceuticals Incorporated	Method of treating pain
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2019209633A1 (en)	2018-04-23	2019-10-31	Pliva Hrvatska D.O.O.	Solid state forms of lorlatinib and their preparation
WO2019210835A1 (zh) *	2018-05-04	2019-11-07	正大天晴药业集团股份有限公司	作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) *	2018-05-07	2020-08-14	昆山国显光电有限公司	手套箱系统以及手套箱系统的保养方法
WO2020059705A1 (ja) *	2018-09-18	2020-03-26	株式会社ヤクルト本社	キノリンカルボキサミド誘導体を用いるがん併用療法
CN109232607A (zh) *	2018-09-20	2019-01-18	沈阳药科大学	劳拉替尼的合成方法
CN109081810A (zh) *	2018-09-20	2018-12-25	沈阳药科大学	1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
US12077528B2 (en)	2018-11-28	2024-09-03	Shenzhen Targetrx, Inc.	Preparation method for deuterated macrocyclic compound
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
CN109651397A (zh) *	2019-01-25	2019-04-19	安庆多辉生物科技有限公司	一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651418A (zh) *	2019-01-25	2019-04-19	安庆多辉生物科技有限公司	一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN109651398B (zh) *	2019-01-25	2021-07-30	安庆多辉生物科技有限公司	一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN111499514B (zh) *	2019-01-31	2024-09-20	连云港润众制药有限公司	一种罗沙司他中间体的制备方法
WO2020190827A1 (en) *	2019-03-21	2020-09-24	Merck Sharp & Dohme Corp.	Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
EP3844166B1 (en) *	2019-05-14	2023-07-12	Teligene Ltd	Substituted macrocycles useful as kinase inhibitors
WO2021011345A1 (en) *	2019-07-18	2021-01-21	Pliva Hrvatska D.O.O	Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) *	2019-08-05	2021-02-05	华东理工大学	大环类jak2抑制剂及其应用
CN110483551B (zh) *	2019-08-30	2021-10-22	北京赛思源生物医药技术有限公司	一种劳拉替尼游离碱的晶体
WO2021069571A1 (en)	2019-10-10	2021-04-15	Sandoz Ag	Polymorph of lorlatinib
CN112812128B (zh) *	2019-11-18	2024-04-02	正大天晴药业集团股份有限公司	作为alk和ros调节剂的大环化合物
CN112824417A (zh) *	2019-11-21	2021-05-21	上海天慈国际药业有限公司	一种劳拉替尼的制备方法
BR112022010924A2 (pt)	2019-12-06	2022-09-06	Vertex Pharma	Tetra-hidrofuranos substituídos como moduladores de canais de sódio
CN111170908B (zh) *	2020-01-09	2021-08-17	北京印刷学院	一种2，4-二甲基-3-甲磺酰基卤苯的合成方法
TW202146017A (zh)	2020-03-05	2021-12-16	美商輝瑞股份有限公司	間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
EP4146205A4 (en)	2020-05-05	2024-05-29	Nuvalent, Inc.	HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
IL297832A (en) *	2020-05-05	2023-01-01	Nuvalent Inc	Macrocyclic heteroaromatic chemotherapeutic agents
WO2021233296A1 (zh) *	2020-05-18	2021-11-25	深圳市塔吉瑞生物医药有限公司	大环化合物的固体形式及其制备和用途
EP4178958A4 (en) *	2020-07-10	2024-12-11	Blossomhill Therapeutics, Inc.	MACROCYCLES AND THEIR USE
WO2022133037A1 (en) *	2020-12-17	2022-06-23	Blossomhill Therapeutics, Inc.	Macrocycles and their use
CN114805371B (zh) *	2021-01-19	2024-05-24	江苏开元药业有限公司	含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) *	2021-02-25	2022-09-01	Blossomhill Therapeutics, Inc.	Macrocycles and their use
EP4320153A1 (en)	2021-04-09	2024-02-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) *	2021-04-26	2022-10-28	苏州东南药业股份有限公司	一类十四元稠环衍生物及其应用
SMT202500481T1 (it)	2021-06-04	2026-01-12	Vertex Pharma	N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
TW202320768A (zh) *	2021-10-01	2023-06-01	美商努法倫特公司	雜芳族大環醚化合物之固體形式、醫藥組成物及製備
CA3244798A1 (en)	2022-02-21	2023-08-24	Universidade Nova De Lisboa	COMPOUNDS AND COMPOSITIONS AGAINST NEURODEGENERATIVE DISEASES
EP4230201A1 (en)	2022-02-21	2023-08-23	Universidade Nova De Lisboa	Composition for treating neurodegenerative diseases
US20250326769A1 (en) *	2022-10-19	2025-10-23	Nuvalent, Inc.	Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023B (zh) *	2022-10-27	2024-08-09	复旦大学	一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2024046512A2 (zh) *	2022-12-01	2024-03-07	中国医药研究开发中心有限公司	含氮大环类化合物及其制备方法和医药用途
WO2024146541A1 (en) *	2023-01-03	2024-07-11	Guangdong Newopp Biopharmaceuticals Co., Ltd.	Macrocyclic compounds as usp1 inhibitors
CN120344244A (zh) *	2023-11-15	2025-07-18	深圳市塔吉瑞生物医药有限公司	治疗alk阳性或ros1阳性的非小细胞肺癌的方法
WO2025212729A1 (en) *	2024-04-03	2025-10-09	Blossomhill Therapeutics, Inc.	Macrocyclic compounds and their use
WO2026008023A1 (zh) *	2024-07-04	2026-01-08	正大天晴药业集团股份有限公司	哒嗪胺类化合物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090286778A1 (en) *	2008-04-24	2009-11-19	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
US20100190804A1 (en) *	2009-01-23	2010-07-29	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
WO2011138751A2 (en) *	2010-05-04	2011-11-10	Pfizer Inc.	Heterocyclic derivatives as alk inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
WO2000035296A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
DE10239042A1 (de)	2002-08-21	2004-03-04	Schering Ag	Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DK1603570T5 (da)	2003-02-26	2013-12-09	Sugen Inc	Aminoheteroarylforbindelser som proteinkinaseinhibitorer
WO2004078682A2 (en)	2003-03-05	2004-09-16	Irm Llc	Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) *	2003-05-27	2014-03-15	شركة جانسين فارماسوتيكا ان. في	Quinazoline derivatives
RU2346996C2 (ru)	2004-06-29	2009-02-20	ЮРОПИЭН НИКЕЛЬ ПиЭлСи	Усовершенствованное выщелачивание основных металлов
CA2578370A1 (en)	2004-08-25	2006-03-02	Pfizer Inc.	Triazolobenzodiazepines and their use as vasopressin antagonists
ES2355923T3 (es)	2004-08-26	2011-04-01	Pfizer, Inc.	Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
DE602005020465D1 (de) *	2004-08-26	2010-05-20	Pfizer	Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
EP1710246A1 (en)	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
PL1959955T3 (pl)	2005-12-05	2011-04-29	Pfizer Prod Inc	Sposób traktowania nieprawidłowego wzrostu komórek
DK1963302T3 (da)	2005-12-05	2013-04-02	Pfizer Prod Inc	Polymorfer af en C-MET/HGFR-inhibitor
JP2010516680A (ja)	2007-01-19	2010-05-20	エックスカバリー，インコーポレイテッド	キナーゼ阻害薬化合物
MX2009008756A (es)	2007-03-01	2009-08-27	Chugai Pharmaceutical Co Ltd	Compuesto macrociclico.
AP2009004985A0 (en) *	2007-03-13	2009-10-31	Pfizer Prod Inc	Erythromycin-based macrolides
EP2265270A1 (en) *	2008-02-04	2010-12-29	OSI Pharmaceuticals, Inc.	2-aminopyridine kinase inhibitors
WO2009146802A1 (de) *	2008-06-06	2009-12-10	Sanofi-Aventis	Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia
KR20110073500A (ko) *	2008-09-08	2011-06-29	메르크 파텐트 게엠베하	오로라 키나아제 억제제로서 마크로사이클릭 피리미딘
US20120258993A1 (en)	2009-10-21	2012-10-11	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US8383793B2 (en)	2010-04-15	2013-02-26	St. Jude Children's Research Hospital	Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
ME03376B (me) *	2010-05-20	2020-01-20	Array Biopharma Inc	Makrociklička jedinjenja kао inhibiтori trk kinaze
US8975232B2 (en)	2010-07-29	2015-03-10	President And Fellows Of Harvard College	Macrocyclic kinase inhibitors and uses thereof
EP2686323A1 (en)	2011-03-16	2014-01-22	Cephalon, Inc.	Macrocyclic compounds as alk, fak and jak2 inhibitors

2013
- 2013-02-20 DK DK13717555.0T patent/DK2822953T5/en active
- 2013-02-20 SG SG11201404451TA patent/SG11201404451TA/en unknown
- 2013-02-20 HU HUE13717555A patent/HUE034118T2/en unknown
- 2013-02-20 LT LTEP13717555.0T patent/LT2822953T/lt unknown
- 2013-02-20 MD MDA20140086A patent/MD4590C1/ro active IP Right Grant
- 2013-02-20 WO PCT/IB2013/051391 patent/WO2013132376A1/en not_active Ceased
- 2013-02-20 RS RS20170280A patent/RS55814B1/sr unknown
- 2013-02-20 ES ES13717555.0T patent/ES2621220T3/es active Active
- 2013-02-20 CA CA2863892A patent/CA2863892C/en active Active
- 2013-02-20 EP EP13717555.0A patent/EP2822953B9/en active Active
- 2013-02-20 AU AU2013229173A patent/AU2013229173B2/en active Active
- 2013-02-20 KR KR1020147027905A patent/KR101692600B1/ko active Active
- 2013-02-20 BR BR112014022106-5A patent/BR112014022106B1/pt active IP Right Grant
- 2013-02-20 HR HRP20170287TT patent/HRP20170287T2/hr unknown
- 2013-02-20 EA EA201491394A patent/EA026155B9/ru active Protection Beyond IP Right Term
- 2013-02-20 GE GEAP201313564A patent/GEP201606560B/en unknown
- 2013-02-20 PL PL13717555T patent/PL2822953T3/pl unknown
- 2013-02-20 PE PE2014001329A patent/PE20142339A1/es active IP Right Grant
- 2013-02-20 NZ NZ627900A patent/NZ627900A/en unknown
- 2013-02-20 PT PT137175550T patent/PT2822953T/pt unknown
- 2013-02-20 MY MYPI2014702342A patent/MY169142A/en unknown
- 2013-02-20 MX MX2014010716A patent/MX350844B/es active IP Right Grant
- 2013-02-20 SI SI201330542A patent/SI2822953T1/sl unknown
- 2013-02-20 AP AP2014007881A patent/AP2014007881A0/xx unknown
- 2013-02-20 ME MEP-2017-42A patent/ME02630B/me unknown
- 2013-02-20 JP JP2014560470A patent/JP5823066B2/ja active Active
- 2013-02-20 CN CN201380012703.XA patent/CN104169286B/zh active Active
- 2013-03-04 AR ARP130100694 patent/AR090230A1/es active IP Right Grant
- 2013-03-04 TW TW102107486A patent/TWI476199B/zh active
- 2013-03-05 US US13/786,106 patent/US8680111B2/en active Active
- 2013-03-06 UY UY34657A patent/UY34657A/es active IP Right Grant
2014
- 2014-01-15 US US14/156,144 patent/US9133215B2/en active Active
- 2014-08-01 CR CR20140370A patent/CR20140370A/es unknown
- 2014-08-06 CL CL2014002084A patent/CL2014002084A1/es unknown
- 2014-08-11 IL IL234062A patent/IL234062A/en active IP Right Grant
- 2014-08-18 DO DO2014000188A patent/DOP2014000188A/es unknown
- 2014-08-25 ZA ZA2014/06244A patent/ZA201406244B/en unknown
- 2014-09-05 NI NI201400102A patent/NI201400102A/es unknown
- 2014-09-05 GT GT201400187A patent/GT201400187A/es unknown
- 2014-09-05 PH PH12014501992A patent/PH12014501992A1/en unknown
- 2014-09-08 CO CO14198153A patent/CO7061081A2/es unknown
2015
- 2015-10-05 JP JP2015197955A patent/JP6002825B2/ja active Active
2017
- 2017-03-27 CY CY20171100376T patent/CY1118771T1/el unknown
2019
- 2019-08-02 CY CY2019033C patent/CY2019033I1/el unknown
- 2019-08-19 NO NO2019034C patent/NO2019034I1/no unknown
- 2019-09-12 HU HUS1900040C patent/HUS1900040I1/hu unknown
- 2019-09-17 NL NL301006C patent/NL301006I2/nl unknown
- 2019-10-01 LU LU00131C patent/LUC00131I2/fr unknown
- 2019-10-18 LT LTPA2019519C patent/LTC2822953I2/lt unknown
- 2019-10-23 FR FR19C1062C patent/FR19C1062I2/fr active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090286778A1 (en) *	2008-04-24	2009-11-19	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
US20100190804A1 (en) *	2009-01-23	2010-07-29	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
WO2011138751A2 (en) *	2010-05-04	2011-11-10	Pfizer Inc.	Heterocyclic derivatives as alk inhibitors

Also Published As

Publication number	Publication date
MX2014010716A (es)	2014-09-22
EA026155B1 (ru)	2017-03-31
PH12014501992B1 (en)	2014-11-24
GT201400187A (es)	2015-10-15
KR20140137414A (ko)	2014-12-02
EP2822953B1 (en)	2017-02-01
AU2013229173B2 (en)	2017-06-01
CY2019033I2 (el)	2019-11-27
NO2019034I1 (no)	2019-08-19
JP2016041709A (ja)	2016-03-31
CR20140370A (es)	2014-08-21
JP6002825B2 (ja)	2016-10-05
FR19C1062I1 (mo)	2019-11-22
HUS1900040I1 (hu)	2019-09-30
PT2822953T (pt)	2017-04-06
HUE034118T2 (en)	2018-01-29
AP2014007881A0 (en)	2014-08-31
PH12014501992A1 (en)	2014-11-24
TW201350484A (zh)	2013-12-16
MY169142A (en)	2019-02-18
NL301006I2 (nl)	2020-04-14
ME02630B (me)	2017-06-20
US20140135339A1 (en)	2014-05-15
WO2013132376A1 (en)	2013-09-12
US8680111B2 (en)	2014-03-25
CA2863892A1 (en)	2013-09-12
ZA201406244B (en)	2015-05-27
NZ627900A (en)	2016-08-26
CO7061081A2 (es)	2014-09-19
RS55814B1 (sr)	2017-08-31
PE20142339A1 (es)	2015-01-15
EP2822953A1 (en)	2015-01-14
EP2822953B9 (en)	2017-06-21
DOP2014000188A (es)	2014-11-16
SG11201404451TA (en)	2014-09-26
SI2822953T1 (sl)	2017-04-26
MD4590B1 (ro)	2018-08-31
CY1118771T1 (el)	2017-07-12
HRP20170287T2 (hr)	2017-11-03
CN104169286B (zh)	2016-06-08
LTPA2019519I1 (lt)	2019-11-11
EA026155B9 (ru)	2017-06-30
CA2863892C (en)	2016-08-30
LUC00131I1 (mo)	2019-10-11
MD4590C1 (ro)	2019-03-31
ES2621220T3 (es)	2017-07-03
BR112014022106B1 (pt)	2022-08-02
LTC2822953I2 (lt)	2020-12-28
JP2015510879A (ja)	2015-04-13
CN104169286A (zh)	2014-11-26
HRP20170287T1 (hr)	2017-04-21
GEP201606560B (en)	2016-10-25
DK2822953T3 (en)	2017-04-03
FR19C1062I2 (fr)	2020-09-04
DK2822953T5 (en)	2017-09-11
EA201491394A1 (ru)	2015-05-29
KR101692600B1 (ko)	2017-01-03
UY34657A (es)	2013-10-31
BR112014022106A2 (pt)	2017-07-11
PL2822953T3 (pl)	2017-07-31
US20130252961A1 (en)	2013-09-26
LT2822953T (lt)	2017-04-10
IL234062A (en)	2017-08-31
JP5823066B2 (ja)	2015-11-25
CL2014002084A1 (es)	2014-11-03
CY2019033I1 (el)	2019-11-27
AU2013229173A1 (en)	2014-08-21
MD20140086A2 (mo)	2015-01-31
NI201400102A (es)	2015-03-05
MX350844B (es)	2017-09-22
ES2621220T9 (es)	2017-11-23
LUC00131I2 (mo)	2020-07-16
AR090230A1 (es)	2014-10-29
HK1199247A1 (zh)	2015-06-26
US9133215B2 (en)	2015-09-15

Publication	Publication Date	Title
TWI476199B (zh)	2015-03-11	用於治療疾病之巨環衍生物
CN107207464B (zh)	2019-10-22	被取代的二氢异喹啉酮化合物
CN104870435B (zh)	2016-12-07	芳基和杂芳基稠合的内酰胺类
CN104603127B (zh)	2016-10-05	补体途径调节剂及其应用
CN105683188B (zh)	2018-02-09	作为fgfr4抑制剂的稠环二环吡啶基衍生物
TWI639602B (zh)	2018-11-01	三環旋轉酶抑制劑
CN101687827B (zh)	2014-04-23	环状基团取代的氨基二氢噻嗪衍生物
WO2022268230A1 (zh)	2022-12-29	作为kif18a抑制剂的化合物
CN106029076A (zh)	2016-10-12	作为bet溴域抑制剂的苯并哌嗪组合物
TW201429975A (zh)	2014-08-01	作為磷脂肌醇 3-激酶抑制劑之吡咯並三嗪酮衍生物
CN110461842A (zh)	2019-11-15	作为tnf活性调节剂的稠合五环咪唑衍生物
CN115413279A (zh)	2022-11-29	P2x3调节剂
HK1199247B (en)	2017-04-28	Macrocyclic derivatives for the treatment of proliferative diseases
HK1240585B (zh)	2020-07-31	被取代的二氢异喹啉酮化合物
WO2022052926A1 (zh)	2022-03-17	芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
HK1208866B (en)	2018-01-12	Aryl and heteroaryl fused lactams
HK1240585A1 (zh)	2018-05-25	被取代的二氢异喹啉酮化合物